164 related articles for article (PubMed ID: 37930588)
1. Pharmacodynamic Drug-Drug Interactions and Bleeding Outcomes in Patients with Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study.
Grymonprez M; Capiau A; Steurbaut S; Boussery K; Mehuys E; Somers A; Petrovic M; De Backer TL; Lahousse L
Cardiovasc Drugs Ther; 2023 Nov; ():. PubMed ID: 37930588
[TBL] [Abstract][Full Text] [Related]
2. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
Grymonprez M; Carnoy L; Capiau A; Boussery K; Mehuys E; De Backer TL; Steurbaut S; Lahousse L
Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):722-730. PubMed ID: 37791408
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in patients with atrial fibrillation and a history of falls using non-vitamin K antagonist oral anticoagulants: A nationwide cohort study.
Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L
Int J Cardiol Heart Vasc; 2023 Aug; 47():101223. PubMed ID: 37252193
[TBL] [Abstract][Full Text] [Related]
4. Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study.
Grymonprez M; Petrovic M; De Backer TL; Ikram MA; Steurbaut S; Lahousse L
Age Ageing; 2023 Mar; 52(3):. PubMed ID: 36934339
[TBL] [Abstract][Full Text] [Related]
5. Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis.
Grymonprez M; Vanspranghe K; Capiau A; Boussery K; Steurbaut S; Lahousse L
Br J Clin Pharmacol; 2022 Jul; 88(7):3039-3051. PubMed ID: 35132677
[TBL] [Abstract][Full Text] [Related]
6. Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death: A Nationwide Cohort Study.
Grymonprez M; Steurbaut S; Capiau A; Vauterin D; Van Vaerenbergh F; Mehuys E; Boussery K; De Backer TL; Lahousse L
Cardiovasc Drugs Ther; 2023 Sep; ():. PubMed ID: 37707648
[TBL] [Abstract][Full Text] [Related]
7. Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding.
Lee MT; Park KY; Kim MS; You SH; Kang YJ; Jung SY
Yonsei Med J; 2020 Sep; 61(9):741-749. PubMed ID: 32882758
[TBL] [Abstract][Full Text] [Related]
8. The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients.
Kim D; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Sung JH; Pak HN; Lee MH; Lip GYH; Joung B
Europace; 2020 Apr; 22(4):547-557. PubMed ID: 31598651
[TBL] [Abstract][Full Text] [Related]
9. Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
Quinn GR; Hellkamp AS; Hankey GJ; Becker RC; Berkowitz SD; Breithardt G; Fava M; Fox KAA; Halperin JL; Mahaffey KW; Nessel CC; Patel MR; Piccini JP; Singer DE
J Am Heart Assoc; 2018 Aug; 7(15):e008755. PubMed ID: 30371223
[TBL] [Abstract][Full Text] [Related]
10. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.
Chang SH; Chou IJ; Yeh YH; Chiou MJ; Wen MS; Kuo CT; See LC; Kuo CF
JAMA; 2017 Oct; 318(13):1250-1259. PubMed ID: 28973247
[TBL] [Abstract][Full Text] [Related]
11. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs.
Wang CL; Wu VC; Chang KH; Tu HT; Kuo CF; Huang YT; Chu PH; Kuo CC; Chang SH
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):147-154. PubMed ID: 31384926
[TBL] [Abstract][Full Text] [Related]
12. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants.
Chan YH; Lee HF; Li PR; Liu JR; Chao TF; Wu LS; Chang SH; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2020 May; 19(1):63. PubMed ID: 32404168
[TBL] [Abstract][Full Text] [Related]
14. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study.
Olsen AS; McGettigan P; Gerds TA; Fosbøl EL; Olesen JB; Sindet-Pedersen C; Staerk L; Lock Hansen M; Pallisgaard JL; Køber L; Torp-Pedersen C; Gislason GH; Lamberts M
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):292-300. PubMed ID: 31742339
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
Chao TF; Chiang CE; Liao JN; Chen TJ; Lip GYH; Chen SA
Chest; 2020 May; 157(5):1266-1277. PubMed ID: 31809694
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Major Bleeding Among Working-Age Adults with Atrial Fibrillation: Evaluating the Effects of Potential Drug-drug Interactions and Switching from Warfarin to Non-vitamin K Oral Anticoagulants.
Feng X; Sambamoorthi U; Innes K; Castelli G; LeMasters T; Xiong L; Williams MU; Tan X
Cardiovasc Drugs Ther; 2018 Dec; 32(6):591-600. PubMed ID: 30315487
[TBL] [Abstract][Full Text] [Related]
17. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
[TBL] [Abstract][Full Text] [Related]
18. Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
Kumar S; Danik SB; Altman RK; Barrett CD; Lip GY; Chatterjee S; Roubin GS; Natale A; Danik JS
Cardiol Rev; 2016; 24(5):218-23. PubMed ID: 26274538
[TBL] [Abstract][Full Text] [Related]
19. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
Xiong Q; Lau YC; Senoo K; Lane DA; Hong K; Lip GY
Eur J Heart Fail; 2015 Nov; 17(11):1192-200. PubMed ID: 26335355
[TBL] [Abstract][Full Text] [Related]
20. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients.
Holm J; Mannheimer B; Malmström RE; Eliasson E; Lindh JD
Eur J Clin Pharmacol; 2021 Mar; 77(3):409-419. PubMed ID: 33029651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
